Article
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
Leukemia - 1 Apr 2004
Perentesis J P, Bhatia S, Boyle E, Shao Y, Shu X Ou, Steinbuch M, Sather H N, Gaynon P, Kiffmeyer W, Envall-Fox J, Robison L L
Abstract excerpt
Activating mutations in the RAS oncogenes are among the most common genetic alterations in human cancers, including patients with acute lymphoblastic leukemia (ALL). We sought to define the frequency and spectrum, and possible prognostic importance, of N- and K-RAS mutations in children with ALL treated with contemporary therapy. Leukemic blast DNA from 870 children was analyzed for the presence of activating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.